5. Conclusions
Despite the small number of patients, the evidence reported in the present analysis confirms that the clinical burden of DDIs in SARS-CoV-2 inpatients is relevant. Moreover, the risk of unexpected and uncommon ADRs, such those referred to psychiatric disorders, was highlighted. In this population, COVID-19 treatments should be used with extreme caution, especially in fragile and polymedicated patients. Although living in the context of a global emergency and looking for an effective therapeutic treatment, drug safety should never be overlooked, especially in the presence of DDIs.